Major clinical interests center on the management of patients with solid cancers in particular mesothelioma and other thoracic malignancies including lung cancer as well as melanoma and other skin cancers including Kaposi sarcoma. To advance the management of these cancers and offer patients with these cancers optimal care, I perform clinical trials for these diseases.
As an IRB vice-chair I appreciate and contribute to the optimization of the mechanisms of clinical trials. Bias in clinical trials and its reduction by statistical methods is of great interest to me as is optimization of clinical research. As Chief of Hematology and Oncology at the Baltimore VA, I am interested in the administration of oncology departments and in improving the safety of patients while preserving effectiveness of cancer care.
Laboratory research is centered on the cellular and tissue level of cancer growth. I study gap junctional intercellular communications, and their function in drug resistance. Phenotypic changes related to the epithelial mesothelial transition are studied in melanoma and mesothelioma. The milky spots of the pleural and peritoneal cavities are studied to better understand the pathogenesis and spread of mesothelioma. Tumor stem cells as the ultimate object of cancer therapy will be studied.